Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Pharnext
  6. News
  7. All News
    ALPHA   FR0011191287

PHARNEXT

(ALPHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about PHARNEXT
11/23GLOBAL MARKETS LIVE : Samsung, Clariant, AstraZeneca, Amazon, Merck...
11/23Pharnext SA Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Resear..
CI
11/22Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research ..
EQ
10/27Présentation du R&D Day 2021
PU
10/19PHARNEXT : Présentation Corporate de Pharnext
PU
10/19PHARNEXT : Names Chief Manufacturing Officer, COO; Shares Up 17%
MT
10/18PHARNEXT : Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Dise..
PU
09/07PHARNEXT : Présentation Corporate de Pharnext
PU
08/31PHARNEXT : Présentation Corporate de Pharnext
PU
08/02PHARNEXT : Présentation Corporate de Pharnext
PU
07/15PHARNEXT :
AQ
07/15PHARNEXT : Piers Morgan Joins Pharnext's Board of Directors
PU
07/12PHARNEXT : Enrolls First Patient in European Phase 3 Study of Rare Genetic Disorder Drug
MT
06/21PHARNEXT : Shareholder Letter
PU
06/21PHARNEXT : Letter to Shareholders
PU
06/07GLOBAL MARKETS LIVE : Toshiba, Facebook, AT&T, Tesla, Blackstone...
06/07PHARNEXT : Announces a New Financing Through a Convertible Bond Program for a Total Amount..
PU
06/07PHARNEXT : Announces a New Financing Through a Convertible Bond Program for a Total Amount..
EQ
05/03PHARNEXT : Présentation Corporate de Pharnext
PU
04/30PHARNEXT : Auditors' report on Financial year 2020
PU
04/30PHARNEXT : Auditors' report on IFRS Financial statement 2020
PU
04/29PHARNEXT : Presentation of the PLEO-CMT-FU Extension Study Update
PU
04/28Pharnext SA Announces New Results from an Interim Analysis from the Ongoing Open-Label ..
CI
04/28PHARNEXT : Une analyse intermédiaire de l'étude de Phase III d'extension en ouvert en cour..
GL
04/28PHARNEXT : Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Su..
PU
04/28Global markets live: Microsoft, Apple, Tesla...
04/27PHARNEXT : 2020 Annual Financial results IFRS
PU
04/27PHARNEXT : French Gaap Financial Statement 2020
PU
04/27PHARNEXT : Reports Financial Results for Year-End 2020
EQ
04/06PHARNEXT : Présentation Corporate de Pharnext
PU
03/31PHARNEXT : Enrolls First Patient In Phase III Trial to Treat Neurological Disorder
MT
03/31PHARNEXT : Présentation Corporate de Pharnext
PU
03/31PHARNEXT : Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Cl..
PU
03/29PHARNEXT : Présentation Corporate de Pharnext
PU
02/05PHARNEXT : Présentation Corporate de Pharnext
PU
02/04PHARNEXT : Announces Financing of Ç11 Million Through a Capital Raise Subscribed by Existi..
PU
02/04PHARNEXT : Announces Financing of ?11 Million Through a Capital Raise Subscribed by Existi..
EQ
02/03Pharnext SA announced that it expects to receive Ç10.999997 million in funding from CB ..
CI
02/01PHARNEXT : Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie..
PU
01/25PHARNEXT : Présentation Corporate de Pharnext
PU
01/11PHARNEXT : Présentation Corporate de Pharnext
PU
2020PHARNEXT : Présentation Corporate de Pharnext
PU
2020PHARNEXT : 2019 Universal Registered Document
PU
2020PHARNEXT : Présentation de la Journée R&D
PU
2020PHARNEXT : Présentation Corporate de Pharnext
PU
2020PHARNEXT : 2019 Universal Registration Document Approved by AMF
PU
2020PHARNEXT : Le Document de Référence Universel 2019 de Pharnext est approuvé par l'AMF (ver..
PU
2020PHARNEXT : 2019 Universal Registration Document Approved by AMF
EQ
2020PHARNEXT : Letter to Shareholders from Dr. David Horn Solomon, Chief Executive Officer
PU
2020PHARNEXT : Shareholder Letter
EQ
2020PHARNEXT : IFRS Financial report first-half 2020
PU
2020PHARNEXT : announces 2020 half-year results
PU
2020PHARNEXT : announces 2020 half-year results
EQ
2020Pharnext Sa Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020PHARNEXT : to Host Research and Development Event Today
PU
2020PHARNEXT : to Host Research and Development Event Today
EQ
2020PHARNEXT : to Host Research and Development Day on October 13, 2020
PU
2020PHARNEXT : to Host Research and Development Day on October 13, 2020
EQ
2020PHARNEXT : and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
EQ
2020PHARNEXT S A : announces approval of resolutions at its Annual General Meeting of 17 July ..
EQ
2020PHARNEXT S A : announces its 2020 Annual General Meeting to be held on July 17, 2020
PU
2020PHARNEXT : announces its 2020 Annual General Meeting to be held on July 17, 2020
EQ
2020PHARNEXT : provides regulatory and clinical update on PXT3003 Phase III study for the trea..
EQ
2020PHARNEXT : Presents a Business Update Webcast on May 20th, 2020
PU
2020PHARNEXT : will hold a Business Overview Webcast on May 20th, 2020
PU
2020PHARNEXT : Presents a Business Update Webcast on May 20th, 2020
EQ
2020Pharnext SA Enters into Agreement with University Hospital Institute Mediterranee Infec..
CI
2020PHARNEXT : Reports Financial Results for Year-End 2019
EQ
2020PHARNEXT : and the University Hospital Institute Méditerranée Infection Announce a Joint E..
PU
2020PHARNEXT : and the University Hospital Institute Méditerranée Infection Announce a Joint E..
EQ
2020Pharnext Sa Reports Earnings Results for the Full Year Ended December 31, 2019
CI
2020PHARNEXT : Announces the Appointment of David Horn Solomon as Chief Executive Officer
PU
2020PHARNEXT : Announces the Appointment of David Horn Solomon as Chief Executive Officer
EQ
2020PHARNEXT : Announces Identification of a Large Set of Frequently Prescribed Drugs to be Re..
EQ
2020PHARNEXT : Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has ..
EQ
1  2  3Next
Upcoming event on PHARNEXT
04/28/22